Davis Polk advised the underwriters in connection with the $487 million SEC-registered initial public offering by Legend Biotech Corporation of 21,188,750 American Depositary Shares, each representing two ordinary shares, which included 2,763,750 ADSs sold pursuant to the underwriters’ over-allotment option. The ADSs are listed on the Nasdaq Global Select Market under the symbol “LEGN.”

Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications.

The Davis Polk capital markets team included partners Richard D. Truesdell Jr., Yasin Keshvargar and Yang Chu and associates Ida Araya-Brumskine, Lillian Lian, Charles York and Shuang Ci. Partner Patrick E. Sigmon provided tax advice. Partner David R. Bauer and associate Jesse L. Hallock provided intellectual property advice. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the New York and Hong Kong offices.

Copy link to share post